Isoquercetin for Ovarian Cancer

Not yet recruiting at 7 trial locations

Overseen By Elizabeth Jewell, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Must be taking: Chemotherapy

Must not be taking: Anticoagulants, Aspirin, NSAIDs

Disqualifiers: Bleeding risk, Brain metastases, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 6 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether isoquercetin, a natural compound, can reduce blood markers that may indicate a risk for blood clots in individuals with ovarian cancer. Researchers compare the effects of isoquercetin taken once or twice daily against a placebo. This study may suit those diagnosed with ovarian cancer and currently undergoing their first round of chemotherapy. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as anticoagulants and daily aspirin or similar drugs, before participating. If you're on these medications, you may need to discuss alternatives with your doctor.

Is there any evidence suggesting that isoquercetin is likely to be safe for humans?

Research has shown that isoquercetin is generally safe for people. Studies have found that even at high doses, isoquercetin does not increase the risk of bleeding, a common concern with blood clot treatments. Other research indicates that isoquercetin does not affect certain proteins linked to cancer growth, allowing it to target cancer cells without harming normal cells. Overall, evidence suggests that isoquercetin is well-tolerated and safe for humans. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for ovarian cancer?

Isoquercetin is unique because it is a naturally derived compound that stands out from standard ovarian cancer treatments, like chemotherapy and targeted therapies. Researchers are excited because isoquercetin has antioxidant and anti-inflammatory properties, which may help inhibit cancer cell growth differently from traditional options. Unlike most treatments, which often have harsh side effects, isoquercetin is being explored for its potential to offer a gentler approach with fewer adverse effects. Additionally, the trial is testing different dosing schedules, like once or twice daily, to optimize its effectiveness, offering more personalized treatment possibilities.

What evidence suggests that isoquercetin might be an effective treatment for ovarian cancer?

Research shows that isoquercetin might help treat ovarian cancer. Studies have found that isoquercetin can slow the growth and spread of ovarian cancer cells by causing a type of cell death that prevents cancer cells from multiplying. Other research indicates that combining isoquercetin with certain chemotherapy drugs can shrink tumors more effectively than chemotherapy alone. These findings suggest that isoquercetin might also reduce the risk of blood clots and could be a useful treatment for ovarian cancer. Participants in this trial will join different treatment arms, including a placebo group and groups receiving isoquercetin either daily or twice daily, to evaluate its effectiveness. ^{1 2 6 7 8}

Who Is on the Research Team?

Jeffrey Zwicker, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with confirmed ovarian cancer who are starting their first round of chemotherapy. They should have a life expectancy over 6 months, be relatively active (ECOG status <2), and have certain blood and liver function levels within set limits. Participants must use birth control due to unknown effects on fetuses.

Inclusion Criteria

I am at least 18 years old.

My doctor expects me to live more than 6 months.

I can do most of my daily activities on my own.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either isoquercetin or placebo to assess its effect on thrombin generation

6 weeks

Weekly visits for monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Isoquercetin

Trial Overview

The study tests if isoquercetin can lower blood markers that suggest a risk of clots in ovarian cancer patients. It's compared against a placebo to see if there's any difference between the two treatments.

How Is the Trial Designed?

Group I: Cohort C: Isoquercetin twice daily Experimental Treatment 1 Intervention

Group II: Cohort B: Isoquercetin daily Experimental Treatment 1 Intervention

Group III: Cohort A: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12755188/

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor ...

Notably, the high‐dose ISOQ combination resulted in tumors 44.3% smaller than chemotherapy alone (p = 0.0376; Figure S1B), suggesting that ISOQ ...

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT07303894

A Study of Isoquercetin in People With Ovarian Cancer

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in ...

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12484485/

Isoquercitrin triggers the ferroptosis of ovarian cancer via ...

Results unveiled that ISOQ dose-dependently repressed the proliferation and migration, and triggered the ferroptosis of ovarian cancer cells.

4.

sciencedirect.com

sciencedirect.com/science/article/pii/S2589004224016596

Article The impact of quercetin and paclitaxel combination ...

This study provides strong evidence that quercetin enhances the effectiveness of paclitaxel in treating ovarian cancer.

5.

withpower.com

withpower.com/trial/phase-2-ovarian-neoplasms-2026-cc15c

Isoquercetin for Ovarian Cancer · Info for Participants

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian ...

6.

faseb.onlinelibrary.wiley.com

faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.202502774R

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor ...

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer.

7.

link.springer.com

link.springer.com/article/10.1007/s12672-025-03626-5

Isoquercitrin triggers the ferroptosis of ovarian cancer via ...

Isoquercitrin (ISOQ) has been identified to exert notable inhibitory effects on tumorigenesis, though its role on ovarian cancer is unknown.

8.

sciencedirect.com

sciencedirect.com/science/article/pii/S0367326X25003922

Isoquercitrin: From natural source to clinical candidate

Other studies have shown that ISQ, at concentrations ranging from 5 to 100 μg/mL, did not affect the release of human TGF-β1 and its receptor in ovarian cancer ...